The CARPO protocol mandates a 30-day treatment and observation period for patients. Credit: Emily frost / Shutterstock.

CalciMedica has announced the completion of patient enrollment for its Phase IIb CARPO clinical trial, which is evaluating the efficacy of Auxora in treating acute pancreatitis.

A new therapy from CalciMedica, Auxora is a potent and selective inhibitor of Orai1-containing calcium release-activated calcium (CRAC) channels.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is being developed to treat acute inflammatory and immunologic illnesses, with a focus on its potential benefits for patients suffering from acute pancreatitis.

The CARPO trial is a global, double-blind, randomised, placebo-controlled, dose-ranging study designed to determine the dose-response and efficacy of Auxora in patients with acute pancreatitis and accompanying systemic inflammatory response syndrome (SIRS).

Patients in the trial have been randomised into four groups to receive varying doses of Auxora or a placebo intravenously every 24 hours for three doses.

The CARPO protocol mandates a 30-day treatment and observation period for patients, with the company set to report topline results later this quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CalciMedica CEO Rachel Leheny said: “We are a significant step closer to delivering a potential treatment for acute pancreatitis, for which there is currently no approved therapy. We look forward to sharing the results of this clinical trial in the coming weeks once the last patient has finished treatment and the data have been analysed.”

In February, the US Food and Drug Administration approved CalciMedica’s investigational new drug application to advance Auxora to a Phase II study.

The KOURAGE trial is designed to analyse the ability of Auxora to treat acute kidney injury with associated acute hypoxemic respiratory failure.